Mostrar el registro sencillo del ítem
dc.contributor.author | Pascual-García, Mónica | |
dc.contributor.author | Bonfill-Teixidor, Ester | |
dc.contributor.author | Planas-Rigol, Ester | |
dc.contributor.author | Rubio-Perez, Carlota | |
dc.contributor.author | Iurlaro, Raffaella | |
dc.contributor.author | Arias, Alexandra | |
dc.contributor.author | Cuartas, Isabel | |
dc.contributor.author | Sala-Hojman, Ada | |
dc.contributor.author | Escudero, Laura | |
dc.contributor.author | Martínez-Ricarte, Francisco | |
dc.contributor.author | Huber-Ruano, Isabel | |
dc.contributor.author | Nuciforo, Paolo | |
dc.contributor.author | Pedrosa, Leire | |
dc.contributor.author | Marques, Carolina | |
dc.contributor.author | Braña, Irene | |
dc.contributor.author | Garralda, Elena | |
dc.contributor.author | Vieito, María | |
dc.contributor.author | Squatrito, Massimo | |
dc.contributor.author | Pineda, Estela | |
dc.contributor.author | Graus, Francesc | |
dc.contributor.author | Espejo, Carmen | |
dc.contributor.author | Sahuquillo, Juan | |
dc.contributor.author | Tabernero, Josep | |
dc.contributor.author | Seoane, Joan | |
dc.date.accessioned | 2019-09-10T11:27:07Z | |
dc.date.available | 2019-09-10T11:27:07Z | |
dc.date.issued | 2019-06-11 | |
dc.identifier.citation | Nat Commun. 2019 ;10(1):2416. | es_ES |
dc.identifier.issn | 2041-1723 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8322 | |
dc.description.abstract | Cancer response to immunotherapy depends on the infiltration of CD8+ T cells and the presence of tumor-associated macrophages within tumors. Still, little is known about the determinants of these factors. We show that LIF assumes a crucial role in the regulation of CD8+ T cell tumor infiltration, while promoting the presence of protumoral tumor-associated macrophages. We observe that the blockade of LIF in tumors expressing high levels of LIF decreases CD206, CD163 and CCL2 and induces CXCL9 expression in tumor-associated macrophages. The blockade of LIF releases the epigenetic silencing of CXCL9 triggering CD8+ T cell tumor infiltration. The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival. | es_ES |
dc.description.sponsorship | We want to thank the Medical Oncology department, the Neurosurgery department, and the Pathology department of the Vall d’Hebron Hospital and Clínic Hospital. We also want to thank Cristina Sánchez for technical support. This work has been funded by theEuropean Research Council grant (ERC 205819), the Asociación Española contra el Cáncer (AECC), FIS - Instituto de Salud Carlos III grant (PI16/01278), MINECO-RETOS RTC-2015-3771-1, the FERO, laCaixa, BBVA (CAIMI) and Cellex foundations. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature Publishing Group | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antibodies, Neutralizing | es_ES |
dc.subject.mesh | CD8-Positive T-Lymphocytes | es_ES |
dc.subject.mesh | Chemokine CCL2 | es_ES |
dc.subject.mesh | Chemokine CXCL9 | es_ES |
dc.subject.mesh | Epigenesis, Genetic | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Immunologic Memory | es_ES |
dc.subject.mesh | Leukemia Inhibitory Factor | es_ES |
dc.subject.mesh | Lymphocytes, Tumor-Infiltrating | es_ES |
dc.subject.mesh | Macrophages | es_ES |
dc.subject.mesh | Mice, Inbred C57BL | es_ES |
dc.subject.mesh | Mice, SCID | es_ES |
dc.subject.mesh | Neoplasm Transplantation | es_ES |
dc.subject.mesh | Neoplasms | es_ES |
dc.subject.mesh | Programmed Cell Death 1 Receptor | es_ES |
dc.subject.mesh | Tumor Microenvironment | es_ES |
dc.title | LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 31186412 | es_ES |
dc.format.volume | 10 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 2416 | es_ES |
dc.identifier.doi | 10.1038/s41467-019-10369-9 | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. European Research Council (ERC) | |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | FERO Foundation | |
dc.contributor.funder | Fundación La Caixa | |
dc.contributor.funder | Fundación BBVA | |
dc.contributor.funder | Cellex Foundation | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2041-1723 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1038/s41467-019-10369-9. | es_ES |
dc.identifier.journal | Nature communications | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Tumores Cerebrales Fundación Seve-Ballesteros | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI16/01278 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RTC-2015-3771-1 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7/205819 | es_ES |
dc.rights.accessRights | open access | es_ES |